Abstract: Prevention of adverse cardiac remodeling after myocardial infarction (MI) remains a therapeutic challenge. Angiotensin-converting enzyme inhibitors (ACE-I) are a wellestablished first-line treatment. ACE-I delay fibrosis, but little is known about their molecular effects on cardiomyocytes. We investigated the effects of the ACE-I delapril on cardiomyocytes in a mouse model of heart failure (HF) after MI. Mice were randomly assigned to three groups: Sham, MI, and MI-D (6 weeks of treatment with a non-hypotensive dose of delapril started 24h after MI). Echocardiography and pressure-volume loops revealed that MI induced hypertrophy and dilatation, and altered both contraction and relaxation of the left ventricle. At the cellular level, MI cardiomyocytes exhibited reduced contraction, slowed relaxation, increased diastolic Ca 2+ levels, decreased Ca 2+ -transient amplitude, and diminished Ca 2+ sensitivity of myofilaments. In MI-D mice, however, both mortality and cardiac remodeling were decreased when compared to non-treated MI mice. Delapril maintained cardiomyocyte contraction and relaxation, prevented diastolic Ca 2+ overload and retained the normal Ca 2+ sensitivity of contractile proteins. Delapril maintained SERCA2a activity through normalization of P-PLB/PLB (for both Ser 16 -PLB and Thr 17 -PLB) and PLB/SERCA2a ratios
INTRODUCTION
Over-activation of the renin-angiotensin system (RAS) plays a critical role in the progression of cardiac remodeling after myocardial infarction (MI) [1] . Evidences for the cardiovascular benefits of angiotensin-converting enzyme inhibitors (ACE-I) have emerged from long-term studies (CONSENSUS, SAVE, AIRE, TRACE, SOLVD) [2] . Indeed, ACE-I lower mortality rates and hospital admissions in patients with left ventricular (LV) dysfunction and progressive heart failure (HF) [3] . Benefits occur mainly via blood pressure reduction, yet there is evidence of blood pressure independent protective effects in coronary disease ( [4] .
Experimental studies have shown that ACE-I therapy delays myocardial remodeling, thus inhibiting the transition to HF [5] [6] [7] . At the clinical level, short-term studies (e.g., CONSENSUS-II, AIRE) suggest that early ACE-I therapy provides significant and rapid benefits [2] . Long-term therapy attenuates morphological and functional alterations related to hypertrophy and fibrosis [8, 9] . In particular, ACE-I therapy blocks the fibrogenic action of angiotensin both in experimental models and in patients. However, the pure anti-remodeling effects of ACE-I through normalization (or prevention) of impaired intracellular Ca 2+ signaling and excitation-contraction coupling as observed in HF (i.e. independent of the blood pressure reduction) at the molecular level have been poorly explored.
After MI, the sustained activation of compensatory neurohormonal systems, coupled with the alteration of various cell signaling and gene expression pathways, triggers a domino effect that leads to severely compromised cardiac function. Changes in cardiomyocyte phenotype are responsible for significant alterations in excitation-contraction (E-C) coupling and proarrhythmogenicity, due to the modification of cellular ion currents and Ca 2+ handling [10] [11] [12] .
Specific therapeutic options to optimize healing and prevent adverse post-MI remodeling are currently lacking [13] . Several studies have shown that ACE-I modify the expression of genes coding for Ca 2+ handling proteins during HF [14] [15] [16] but the functional consequences are not well-established. In addition, no study has evaluated the effects of ACE inhibition on myofilament Ca 2+ sensitivity, a key determinant of contraction, during HF.
The ACE-I delapril is an old molecule but still currently used, in combination with Ca
2+
antagonist manidipine, as a therapeutic option to control hypertension complicated by diabetes and microalbuminuria, and to reduce cardiovascular morbidity and mortality in high-risk patients [17] . Interestingly, all ACE-I do not have exactly the same molecular effects and pharmacological properties. The affinities of the enzymatic carboxyterminal and aminoterminal regions (C-site and N-site) of ACE for ACE-I drugs differ according to the organ involved and the two catalytic sites may control different functions [18, 19] . Delaprilat, the active metabolite of delapril, binds with higher affinity to the C-site than to the N-site, in particular in the left ventricle (LV) and reduces cardiac hypertrophy [20] . By comparison, the ACE-I captopril displays a high affinity for the N-site and has less affinity for the myocardium [18, 19] . In the present work, we focused on the independent blood pressure effects of a chronic treatment with delapril, started 24 hours after MI in mice, on surviving LV cardiomyocytes. The study focused on the molecular effects of delapril not only on Ca
handling but also on Ca 2+ sensitivity of myofilaments which, to our best knowledge, has never been studied before. Delapril preserved the contractile properties of cardiomyocytes by reducing the Ca 2+ transient alterations and by preventing the alterations of myofilament contractile properties in HF after MI. hours after surgery and lasting for 6 weeks. This dose was chosen because delapril given for 3 weeks did not lower BP in conscious PMI rats [22] . A complete morphological and functional cardiac evaluation was performed at this stage as described [23] before cellular and molecular studies.
MATERIALS AND METHODS

MI model and experimental groups
Echocardiography
Longitudinal transthoracic echocardiography was carried out in awake mice using a sonographic apparatus equipped with an i13L 14 MHz linear array transducer designed for the examination of small rodents (Vivid 7, GE Medical systems, USA). Mice were trained for several days before the examination in order to decrease the stress due to handling. No difference in heart rate (bpm) was observed within the 3 groups (701±10, 702±10, 715±11, in
Sham, Mi and MI-D respectively). Only mice with a large infarct and an atrial diameter of more than 1.9 mm were used to ensure the transition to HF.
Pressure-volume (P-V) analysis
Briefly, a 1F dual-field combination pressure-conductance catheter (model PVR-1045, Millar
Instruments) connected to a pressure-conductance unit (MPVS-300, Millar) was inserted in the right carotid artery and advanced into the LV of anesthetized mice (isoflurane 1.5-2%).
Changes in LV function were visualized through the use of ventricular pressure-volume (P-V)
loops. Measurements were acquired at rest and after dobutamine infusion (5 g.kg -1 .min -1 ).
Steady-state LV pressure levels were determined during suspended ventilation, and signalaveraged data from 5-10 consecutive beats were used. Parallel conductance from surrounding structures was calculated by injecting a 10 µL bolus of 15% NaCl through the femoral vein.
Load-independent parameters of contractility were derived from the P-V relationship as described [24] . The mean arterial pressure and the maximal (+dP/dt) and minimal (-dP/dt) first derivatives of LV pressure were calculated with IOX v1.8.9.4 software (EMKA Technologies, France).
Quantification of fibrosis
Interstitial fibrosis was measured in 10 μm thick transverse sections of mouse hearts in the peri-infarcted area [25] to assess the effect of delapril on this parameter. Briefly, after cervical dislocation, hearts were excised from mice, rapidly frozen in liquid nitrogen and stored at -80 °C. Collagen distribution was determined using picrosirius red-stained sections and expressed as a percentage of total LV surface area (Histolab, Gothenburg, Sweden).
Cell Contractility and Ca
2+ -Transient Measurements
LV myocytes were freshly isolated from the non-infarcted free wall and recorded as previously described [26] . For measurements of intracellular Ca 2+ , confocal images were simultaneously recorded using an IonOptix system (Milton, MA) and used specifically for the measurement of diastolic Ca 2+ . To do this, LV myocytes were incubated for 30 min with indo-1 AM (10 μmol/L Invitrogen inc. France) as previously described [27] . Cells were field stimulated to contract at 1 Hz. All experiments were performed at room temperature.
Force Measurements in Permeabilized Cardiomyocytes
Isometric force was measured in single permeabilized cardiomyocytes at different Ca
2+
concentrations at an SL of 1.9 µm as described [27] . Force was normalized to the crosssectional area measured from imaged cross-sections, and the force-pCa relation fitted to a Hill equation. In some experiments, myofilaments have been incubated with the catalytic domain of PKA (100 U/mL; Sigma-aldrich, Paris, France) or PKC (0.25 U/mL; Sigma) for 50 min at room temperature.
Real-time PCR
RNA was isolated and analyzed using standard methods. Tissue from the non-infarcted free wall of LV was dissected (n=6 in each group) and flash-frozen in liquid nitrogen. Gene Myofilament proteins: Myofibrillar proteins were analyzed in skinned muscle strips from the non infarcted area of the LV. The heart was pre-skinned by perfusion with a relaxing solution containing 1% Triton X-100 and protease inhibitors, for 10 min. Phosphorylated and nonphosphorylated forms of myosin light chain 2 (MLC-2) were separated on a 10% urea gel and detected with an antibody specific to cardiac MLC-2 (Coger SA, Paris, France). TnI and PKC-α was separated by 15% SDS-PAGE and membranes were incubated with specific antibodies against total cardiac TnI (Cat#4T21, Hytest, Turku, Finland), the PKA-phosphorylated form of cardiac TnI (Cat#4T45, Hytest), PKC-α ((Upstate, Biotechnology, Milton Keynes, UK) or the phospho-Ser657 PKCα (Santacruz, Heidelberg,Germany). All gels were run in triplicate.
Statistical analysis
All data are expressed as means ± S.E.M. Statistical tests included the Mann-Whitney U test, a one-way analysis of variance (ANOVA) when more than two groups were compared, and a Newman-Keul's multiple comparison test for paired values. Differences were considered significant when the P-value was less than 0.05.
RESULTS
Survival, myocardial function and remodeling
We compared survival in Sham, MI and MI-D mice. Survival declined rapidly in the MI group compared to Sham, while Delapril (MI-D) prevented the high mortality observed in the MI group (Fig.1A) . Kaplan-Meier analysis showed that the survival of MI-D mice (87%, n=29) was higher than that of MI mice (62%, n= 49; P < 0.05) but not different from the survival of Sham animals (92%, n=24). The body weights (BW, g) of Sham, MI and MI-D mice were indistinguishable (Table 1) . However, the heart weight (HW, mg) to BW ratio (HW/BW) was higher in MI than in Sham mice, confirming cardiac hypertrophy, which was reduced by delapril ( Table 1) . The mean arterial blood pressure was similar in Sham (89.3±2.6 9 mmHg, n=4) and MI (87.9±10.6 9 mmHg, n=4) mice, as reported before (28), and was not modified by delapril in MI-D animals (88.3±2.9 mmHg, n=4), suggesting that the cardiac effects of delapril were independent of blood pressure reduction.
In terms of cardiac morphology and function, 2D echocardiography in vivo (Fig.1B) showed that MI mice had an augmented LVM (Fig.1C) and LV dilation as assessed by the enddiastolic diameter (LVEdD) ( Table 1) . Posterior wall thickness (PWT) was reduced in MI and MI-D mice as compared to Sham mice (Table 1) . Delapril treatment prevented the increase of the LVM (Fig.1C ) and attenuated LV dilation (Table 1) . At the functional level, MI hearts exhibited a dramatic reduction of the shortening fraction (SF) ( Table 1) , reflecting a major alteration of ventricular function. Although MI-D mice exhibited signs of improved systolic function, the benefit was small (Table 1) , consistent with the extensive cardiomyocyte necrosis caused by the large infarct of the LV in this model.
We further evaluated cardiac function based on LV pressure-volume relationships in vivo. In MI mice, the LV end-diastolic pressure (LVEdP) and LV end-systolic pressure (LVEsP) were, respectively, higher and lower than in Sham mice (Table 1) . Furthermore, the maximal slope of the increment of systolic pressure (dP/dt max), an index of myocardial contractility, was decreased whereas the maximal slope of the increment of diastolic pressure (dP/dt min), an index of relaxation, was increased (Table 1) . MI mice also exhibited larger LV cavity volumes (end systolic and diastolic) than Sham animals. Delapril treatment had no effect on LVSP,
confirming that the dose of delapril used did not reduce blood pressure (Table 1) . However, it attenuated the effect of MI on LV cavity volume with a remarkable benefit in terms of diastolic pressure (Table 1) . Picrosirius red staining showed interstitial and scar fibrosis in the hearts of MI mice (vs. Sham) (Fig.1D,E) . The expression of both collagen I and collagen III mRNAs ( Fig.1F ) was higher, consistent with the phenotype of HF at the molecular level.
Delapril treatment attenuated both fibrosis and collagen I mRNA expression.
Cell contraction and Ca 2+ transients
We next investigated the effect of delapril on cardiomyocytes isolated from the non-infarcted area comprised of viable cells subjected to cardiac remodeling following the MI. In unloaded intact single cardiomyocytes from MI mice (vs. Sham), sarcomere length (SL) shortening, reflecting cell contraction during field stimulation, was decreased ( Fig.2A,B) . Contraction and relaxation velocities were also reduced (Fig.2C) . Delapril treatment prevented all of these changes. Notably, the diastolic SL was larger in MI-D than in MI or even Sham mice, consistent with the remarkable effect of delapril on cell relaxation (Fig.2D) .
We measured the Ca 2+ transients of field-stimulated cardiomyocytes loaded with fluo-4 AM.
The amplitude of Ca 2+ transients was smaller in MI mice (2.3±0.1, n=25) than in Sham mice (3.2±0.2, n=33; P < 0.05) (Fig.3A) . Their time to peak and decay (τ) were delayed in MI mice (Fig.3A) . In parallel, we determined that the Ca 2+ content of the SR, assessed by a challenge with caffeine leading to full Ca 2+ release, was lower in MI mice than in Sham mice (Fig.3B) , which could account for the decrease in the Ca 2+ -transient amplitude. All these alterations were partially prevented by treatment with delapril, which had a astonishing effect on Ca 2+ -transient decay kinetics (Fig.3A) . We further investigated diastolic Ca 2+ using the ratiometric indicator indo-1. Diastolic Ca 2+ was higher in MI mice than in Sham mice, an increase that was completely prevented by delapril (Fig.3C) . Delapril treatment thus, had a notable effect on cell relaxation, Ca 2+ -transient decay and diastolic Ca 2+ .
Expression of Ca 2+ handling proteins
We measured the expression level of Ca 2+ handling proteins involved in E-C coupling (Fig.4) . (Fig.4A) . In contrast, its phosphorylated form (P-RyR) was increased, and this increase was resistant to delapril treatment (Fig.4A ).
The slowing of Ca 2+ -transient decay, as seen in MI cells (Fig.3) (Fig.4B) . Delapril treatment had no effect on the reduction of SERCA2a abundance but remarkably, prevented the increase of PLB protein and phosphorylation levels. Importantly, both the decrease in the P-PLB/PLB ratio (for both Ser 16 -PLB and Thr 17 -PLB) and the increase in the PLB/SERCA2a ratio induced by MI were abolished by delapril (Fig.4C ). (Fig.5D ) suggesting post-translational modifications of regulatory contractile proteins mediated by kinases. We next evaluated the contribution of kinases such as PKA and protein kinase C (PKC) to modulation of Ca 2+ sensitivity in MI and MI-D mice by incubating myofilaments with the two activated kinases. PKA had no effect on maximal tension in the three groups (Fig.6A) . PKA decreased myofilament Ca 2+ sensitivity in both where it remained higher than in Sham and MI, suggesting that delapril protects myofilament Ca 2+ sensitivity by a pathway independent of PKA signaling. Next, we explored the PKC signaling pathway known to be involved in angiotensin II effects through AT1R binding [24] , and to regulate the myofilament function during HF [33] . Incubation of the myofilaments with activated PKC decreased the maximal tension in the three groups to a similar level (Fig.6A) .
Ca
PKC also decreased the pCa 50 in Sham and MI-D mice by 0.18 and 0.12 pCa unit, respectively, but had no effect in MI mice with a non-significant decrease of pCa 50 of 0.03 pCa unit (Fig.6B) . Altogether the results indicate that myofilament function is affected by both PKA and PKC pathways in MI mice while PKC signaling is downregulated in MI-D mice. We thus determined the expression level of PKC-α and its activation evaluated by the level of phosphorylation at Ser 657 (Fig.6C) . The expression and activation of PKC-α increased in MI mice. Delapril treatment prevented the increase in PKC-α expression and did not affect the level of activation compared with MI animals (Fig.6C) . [12, 34, 35] . At the protein level, HF remodeling was associated with changes in the abundance and/or phosphorylation levels of Ca 2+ -handling proteins, including SERCA2a, PLB and RyR2, consistent with earlier reports [12, 34, 35] .
DISCUSSION
ACE-I are among the most beneficial drugs used in HF patients. ACE-I therapy improves survival after MI, and large clinical trials point to the importance of initiating therapy as early as possible [3, 36] . In our MI mouse model, chronic treatment with a non-hypotensive dose of delapril (6 mg/kg) reproduced the expected cardiac effects of ACE-I, including attenuated LV chamber dilation, increased LVM, reduced myocardial fibrosis and collagen production [37] .
Similar beneficial effect has been described with perindopril, which prevents cardiac hypertrophy without affecting systemic blood pressure in the rat with HF after MI [38] . The anti-fibrotic effects of delapril were also comparable to those of a non-hypotensive dose of fosinopril (1 mg/kg; compared to a 25 mg/kg antihypertensive dose), which has also been shown to restore the ß-adrenergic signal transduction pathway independently of the regression of hypertrophy [39] . Our data are consistent with ACE inhibition delaying the transition from hypertrophy to HF by targeting mechanisms intrinsic to cardiomyocytes, in addition to its antifibrotic effects [40] .
A major finding of our study, focused on the post-MI remodeling of cardiomyocytes, was that delapril preserved the normal contraction/relaxation cycle and attenuated SR dysfunction in the surviving cells. Delapril stabilized the amplitude and the onset of contraction through the normalization of Ca 2+ -transient amplitude and kinetics, in line with reports showing improved cell shortening, Ca 2+ -transient amplitude and SERCA2a activity in aortic-banded rats and guinea-pigs treated with the ACE-I ramipril [40, 41] . In our model, delapril did not affect the level of expression of SERCA2a and NCX. We propose that delapril promotes efficient reuptake of Ca 2+ into the SR by maintaining SERCA2a activity through normal P-PLB/PLB (for both P S16 -PLB and P T17 -PLB) and PLB/SERCA2a ratios [29, 30, 42] . In addition, delapril attenuated the reduction in RyR2 abundance in viable cardiomyocytes (see also [43] ), thereby favoring Ca 2+ release in systole. Surprisingly, the higher PKA-phosphorylation level of RyR2, which has previously been associated with Ca 2+ leakage from the SR in HF [44] , was not prevented by delapril. Therefore, if we were to assume that RyR2 was still leaky in the presence of delapril, which might explain the lower SR Ca 2+ content, the beneficial effect of delapril on SERCA2a activity was enough to maintain the normal decay of the Ca 2+ transient (and relaxation) and normal diastolic cytoplasmic Ca 2+ . Several group proposed an increase of NCX expression as an important mechanism to rescue the compromised SERCA2a function in HF in both human [45] [46] [47] and experimental models [48, 49] . Surprisingly, we noted no change in the NCX expression in MI and MI-D mice, which may be in line with evidence for different phenotypes in HF (hearts with increased NCX and unchanged SERCA2a; and hearts with decreased SERCA2a and unchanged levels of NCX) [45] although other groups reported a decrease of NCX during HF [50] [51] [52] .
Another key finding of our study was that delapril treatment preserved the maximum Ca 2+ -saturated active force and Ca 2+ sensitivity of myofilaments in surviving cardiomyocytes after MI. In MI mice, the altered Ca 2+ sensitivity of myofilaments involves the increased activity of both PKA and PKC (Fig.6B) , leading notably to the phosphorylation of cTnI, as previously shown in other rodents [33, 53] . In the present study, the abnormal function of the troponin complex, related to the augmented phosphorylation of cTnI in MI, was prevented by delapril. showing that imidapril and/or ramipril can block early cardiac remodeling via angiotensin receptor (AT1)-dependent mechanisms [54] [55] [56] . It has been recently proposed that during HF downregulation of β-receptor signaling and PKA phosphorylation of cTnI exposes sites for phosphorylation to an already hyperactive PKC-α, which then hyperphosphorylates cardiac troponin I at Ser 23, 24 and thus promotes myofilament decompensation [57] . Previous studies in reconstituted filaments showed that PKC isozymes can cross phosphorylate cTnI at Ser 23, 24 sites [58, 59] . Therefore, delapril may change phosphorylation level of TnI by decreasing PKC signaling pathway. These mechanisms warrant further investigation.
In conclusion, the beneficial effect of ACE-I therapy with delapril on adverse cardiac remodeling occurs by limiting both the fibrosis, with consequences on myocardial wall stiffness, and the loss of contraction of viable cardiomyocytes. Normal contractility and relaxation were preserved due to the prevention of diastolic Ca 2+ overload and the loss of myofilament Ca 2+ sensitivity. The mechanisms underlying these effects seem to be related to the maintenance of SERCA2a activity and the reduction of PKCα expression, respectively, in cardiomyocytes. Our data support a major role for ACE-I in the regulation of the functions of SERCA2a and PKC in the post-ischemic failing heart. Associated with a reduction in fibrosis, this may explain the survival benefits of ACEI therapy in clinical studies, through the improvement of cardiac function, by maintaining excitation-contraction coupling of viable cells.
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